Aug. 17 at 6:23 PM
$CGTX great publication and an earnings report that was more pleasant than I ever expected during a lull period.
I look at what is going on with ANVS and AVXL, and, as much as I hope for success for all players to combat these awful diseases, I have more faith and trust in the team at Cognition. They aren't hyping their drug, they are doing the groundwork and getting it done to get past the hurdles that plague most biotechs.
Runway extended, patent extensions, great publications and validation; I look forward to the START readout. Anything can happen in bio, so always prepare yourself for any eventuality, but something about cognition feels very unique and positive from a scientific and clinical perspective.
The journey is very testing, but I feel there will be immense reward at the end. Time will tell. Good luck to all.
